Incanthera PLC (AQSE:INC) said it has filed a new patent application covering its Sol sun cream used to prevent a skin condition called solar keratosis and related cancers.
If granted, it will further extend the life of the patent family protecting Sol to 2041.
“This new patent filing demonstrates the robust foundations of our Sol programme and strengthens the commercial protection for the product,” Incanthera chairman Tim McCarthy said in a statement. “We are looking forward to the next steps as we bring Sol forward to market-facing partners.”
Sol has already completed the proof of concept stage and Incanthera is looking for a partner to help it through the product development and marketing stage.
Originally spun-out from Bradford University’s Institute of Cancer Therapeutics, the technology uses a formulation and prodrug targeting technologies to deliver treatment specifically to the tumour.